⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NRSN News
NeuroSense Therapeutics Ltd. Ordinary Shares
JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity
prnewswire.com
NRSNW
NRSN
PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference
prnewswire.com
NRSNW
NRSN
NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS
prnewswire.com
NRSNW
NRSN
NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition
prnewswire.com
NRSN
NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease
prnewswire.com
NRSN
World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB
prnewswire.com
NRSN
NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study
prnewswire.com
NRSN
Amyotrophic Lateral Sclerosis Market Outlook: Expanding Therapeutic Pipeline and Novel Drug Launches Propel Growth Throughout Forecast Period (2025-2034) | DelveInsight
prnewswire.com
NRSN
IONQ
MNOV
CLNN
RVSN
BIIB
ABSI
CLNE
NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026
prnewswire.com
NRSN
NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS
prnewswire.com
NRSN